drugset / Trial / NCT00842582
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical trial for women with newly diagnosed ovarian cancer. The purpose of this study is to determine if the addition of a drug called azacitidine (Vidaza®)when added to carboplatin and paclitaxel will change the genetic material of the tumor so that the chemotherapy drugs work better. The study will also determine what the maximum tolerated dose of azacitidine that may be safely used in combination with carboplatin and paclitaxel.
Timeline
- Start
- 2009-02
- Primary completion
- 2011-03
- Completion
- 2011-03
Outcome
Outcome not reported
Stopped (Enrollment): “No enrollment. Unable to recruit due to lack of eligible patients.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 20 mg/m2 | Subcutaneous |
| Subject | Azacitidine | Other / unclassified | 40 mg/m2 | Subcutaneous |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |